BPC-157

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide originally derived from a protein fragment found in human gastric juice. The preclinical research base spans tendon and ligament repair, gut and intestinal healing, wound healing, cardiovascular and central nervous system effects, and a range of musculoskeletal applications - largely studied in rat and mouse models, with smaller cell-culture and biochemistry literature. The human clinical literature is much smaller: only a handful of small published clinical studies exist, and the FDA does not currently recognize BPC-157 as an approved drug or supplement. The regulatory status is a meaningful caveat for any consumer-level consideration of the compound.

The outcome dimensions covered most heavily in the preclinical literature are tendon and ligament healing in rodent injury models, gastrointestinal tract repair in animal models of induced injury, wound healing kinetics, and a wide range of organ-protective effects observed in various rodent models. The much smaller human literature has examined a limited subset of these applications, primarily in case reports and small pilot studies, without the systematic-review-grade synthesis that would support standard consumer-supplement claims.

The defining feature of the BPC-157 literature is the gap between preclinical and clinical evidence. Most consumer marketing claims are extrapolated from rat studies, and the assumption that effects translate to humans at supplemental doses has not been verified in adequately-powered clinical trials. The supplement is typically sold via compounding pharmacies and online sources rather than through standard supplement-retail channels because of the regulatory status; product quality, purity, and dose accuracy can vary substantially across sources. Self-administered injection (the most-common route discussed in consumer communities) introduces additional practical considerations beyond standard oral supplementation.